DrugPatentWatch Database Preview
Endo Pharms Inc Company Profile
What is the competitive landscape for ENDO PHARMS INC, and what generic alternatives to ENDO PHARMS INC drugs are available?
ENDO PHARMS INC has five approved drugs.
There are fourteen US patents protecting ENDO PHARMS INC drugs.
There are two hundred and thirty-five patent family members on ENDO PHARMS INC drugs in forty-two countries and four supplementary protection certificates in four countries.
Summary for Endo Pharms Inc
| International Patents: | 235 |
| US Patents: | 14 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Endo Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Pharms Inc | AVEED | testosterone undecanoate | INJECTABLE;INTRAMUSCULAR | 022219-001 | Mar 5, 2014 | RX | Yes | Yes | 7,718,640 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | 9,101,540 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Endo Pharms Inc | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | RX | Yes | Yes | 7,879,349 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Endo Pharms Inc | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | RX | Yes | Yes | 8,003,353 | ➤ Sign Up | ➤ Sign Up | ||||
| Endo Pharms Inc | COLY-MYCIN S | colistin sulfate; hydrocortisone acetate; neomycin sulfate; thonzonium bromide | SUSPENSION/DROPS;OTIC | 050356-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | 9,107,827 | ➤ Sign Up | ➤ Sign Up | |||
| Endo Pharms Inc | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | RX | Yes | Yes | 9,415,007 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Endo Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 5,145,684 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 250 mg/mL | ➤ Subscribe | 2014-06-11 |
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
Non-Orange Book US Patents for Endo Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,198,795 | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions | ➤ Sign Up |
| 8,652,464 | Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer | ➤ Sign Up |
| 8,236,352 | Glipizide compositions | ➤ Sign Up |
| 7,927,627 | Nanoparticulate fibrate formulations | ➤ Sign Up |
| 6,316,029 | Rapidly disintegrating solid oral dosage form | ➤ Sign Up |
| 7,850,995 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers | ➤ Sign Up |
| 8,309,136 | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Endo Pharms Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Norway | 335179 | ➤ Sign Up |
| Mexico | PA04002395 | ➤ Sign Up |
| Eurasian Patent Organization | 023686 | ➤ Sign Up |
| Australia | 7993800 | ➤ Sign Up |
| China | 101797233 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2009114695 | ➤ Sign Up |
| Japan | 4842514 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Endo Pharms Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00071 | Netherlands | ➤ Sign Up | PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920 |
| 02/028 | Ireland | ➤ Sign Up | PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013 |
| C/GB02/027 | United Kingdom | ➤ Sign Up | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 |
| C0003 | France | ➤ Sign Up | PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
